H.C. Wainwright downgraded Lumos Pharma (LUMO) to Neutral from Buy with a price target of $4.25, down from $28, after the company entered into a definitive merger agreement whereby Double Point Ventures will acquire 100% of Lumos’ outstanding shares of common stock at a price of $4.25 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUMO: